Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 547 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: blood volume measurement Clear all
Completed Early Phase 1 Interventional

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

NCT03763643
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Rituximab, Plasmapheresis
Drug · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
1 Year to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Tuscaloosa, Alabama • Davis, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 25, 2026, 8:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reproductive Capacity and Iron Burden in Thalassemia

NCT02308904
View directory record Official record
Conditions
THALASSEMIA MAJOR
Interventions
Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
12 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 25, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 25, 2026, 8:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Body Vibration and External Load Exercise Training on Cardiovascular and Autonomic Function in Obese Individuals

NCT02679898
View directory record Official record
Conditions
Obesity
Interventions
Unloaded-Whole Body Vibration (WBVT), Loaded-Whole Body Vibration (WBVT)
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 25, 2026, 8:57 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

NCT03259425
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, HF10
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Sep 25, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Investigation of Cocaine Addiction Using mGluR5 PET and fMRI

NCT03471182
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Psychiatric and Cognitive Testing, Cocaine Self-adminstration, Positron Emission Tomography, Magnetic Resonance Imaging
Behavioral · Drug · Radiation + 1 more
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 25, 2026, 8:57 PM EDT
Terminated Not applicable Interventional

Impact of Intraoperative Cell Salvage

NCT06240117
View directory record Official record
Conditions
Peripartum Anemia
Interventions
Intraoperative cellular salvage
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 25, 2026, 8:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Acute Normovolemic Hemodilution on Urine Neutrophil Gelatinase-associated Lipocalin Levels

NCT05349292
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
ANH
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 25, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

NCT01287039
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
26
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 25, 2026, 8:57 PM EDT
Terminated Phase 1 Interventional

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

NCT00376519
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 25, 2026, 8:57 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Autoimmune Basis for Postural Tachycardia Syndrome

NCT02725060
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Tachycardia, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, Orthostatic Intolerance, Cardiovascular Diseases, Primary Dysautonomias
Interventions
phenylephrine, isoproterenol, 25 micro-Ci of radiation, Posture study with blood samples, 24-hour heart rhythm and blood pressure monitoring, Quantitative Axonal Sudomotor Reflex Testing, Autonomic function tests, Rebreathing test, Assessment of splanchnic capacitance, microneurography
Drug · Radiation · Procedure + 1 more
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 25, 2026, 8:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 25, 2026, 8:57 PM EDT
Completed Not applicable Interventional

Adolescent Idiopathic Scoliosis (AIS) Gold Standard for Blood Loss

NCT03990376
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Radioisotope I-131-labeled albumin
Other
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 25, 2026, 8:57 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

NCT04044690
View directory record Official record
Conditions
Dermatomyositis
Interventions
human immunoglobulin G, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
15
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 25, 2026, 8:57 PM EDT
Recruiting Phase 1 Interventional

Adia Med of Winter Park LLC Lower Back Pain Research Study

NCT07587047
View directory record Official record
Conditions
Chronic Mechanical Lower Back Pain, Lower Back Pain, Chronic Lower Back Pain
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Placebo IV
Biological · Other
Lead sponsor
Adia Med of Winter Park LLC
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 25, 2026, 8:57 PM EDT
Completed No phase listed Observational

The Characterization of Blood Volumes of Commercially Available Lancing Devices

NCT01914302
View directory record Official record
Conditions
Diabetes
Interventions
Delica Lancing Device, Flash Lancing Device, Easy Touch Lancing Device, Glucoject Lancing Device, Microlet Lancing Device, Multiclix Lancing Device, Fastclix Lancing Device, Reli-On Lancing Device
Device
Lead sponsor
Facet Technologies
Other
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 25, 2026, 8:57 PM EDT
Active, not recruiting Not applicable Interventional

CT for Personalized Mechanical Ventilation

NCT05977153
View directory record Official record
Conditions
Ventilator-Induced Lung Injury, Sepsis Syndrome, Mechanical Ventilation Complication
Interventions
PEEP (positive end-expiratory pressure) - maximum, PEEP (positive end-expiratory pressure) - standard
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 25, 2026, 8:57 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00411801
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
Uniplas, Cryosupernatant plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Centreville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 25, 2026, 8:57 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Noninvasive Monitor of Vascular Volume Fluid Shifts

NCT05080881
View directory record Official record
Conditions
Blood Loss
Interventions
phonocardiographic measurement: InnoVital Systems, phonocardiographic measurement: ThinkLabs StethOne, physiological measurements: BIOPAC, physiological measurements: Masimo Radical-7, physiological measurements: CoVa Monitoring System 2, Thoracic impedance
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 25, 2026, 8:57 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT06763549
View directory record Official record
Conditions
Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions
SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 25, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 25, 2026, 8:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Influences of Long-acting Reversible Contraceptives on Iron Status and Physiological Responses to Extreme Environments in Women

NCT06909695
View directory record Official record
Conditions
Contraception, Iron Deficiencies
Interventions
Blood volume and environmental testing
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 25, 2026, 8:57 PM EDT
Not listed Phase 4 Interventional

Denosumab Administration After Spinal Cord Injury

NCT01983475
View directory record Official record
Conditions
Osteoporosis, Spinal Cord Injury
Interventions
Denosumab, Placebo (identical Denosumab volume of normal saline)
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 25, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

NCT00286182
View directory record Official record
Conditions
Anemia
Interventions
Erythropoietin alpha, Placebo
Drug
Lead sponsor
Mathew S. Maurer
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 25, 2026, 8:57 PM EDT